A self-curing absorbable bone filling material and its application

By using a combination of calcium hemihydrate sulfate and bioactive glass in the self-curing absorbable bone filler material, and adding sodium carboxymethylcellulose and porous bioactive glass, the problems of small pore size and porosity and poor injection performance are solved. The appropriate coagulation time and mechanical strength are achieved, which promotes cell ossification and reduces the risk of infection, and matches the growth rate of new bones in the human body.

CN118649288BActive Publication Date: 2024-11-22SHANGHAI PENGGUAN BIOMEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411140191.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-22
Estimated Expiration
2044-08-20

AI Technical Summary

Technical Problem

The existing self-curing absorbable bone filler materials have a long degradation time, small pore size and pores of in-situ curing materials, poor injection performance, easy to crumble during implantation, which is not conducive to the growth of osteoblasts and blood vessels, and are prone to release a large amount of heat. , there is a problem of infection after surgery.

Method used

Using a combination of calcium sulfate hemihydrate and bioactive glass, sodium carboxymethylcellulose is added as a thickener, and porous bioactive glass and antibacterial components are used to prepare porous bioactive glass by sol-gel method to form an appropriate solidification time and mechanical strength, promotes cell ossification and reduces the risk of infection.

Benefits of technology

The appropriate coagulation time, good mechanical strength and anti-flushing performance are achieved, which promotes cell ossification, avoids postoperative infection, improves the generation of new bones, and the degradation rate of the material matches the growth rate of new bones in humans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118649288B_ABST
    Figure CN118649288B_ABST
Patent Text Reader

Abstract

The present invention provides a self-curing absorbable bone filling material and application, the self-curing absorbable bone filling material comprises a solid phase base component and a curing liquid, the solid phase base component comprises 40-60 parts of hemihydrate calcium sulfate and 40-60 parts of bioactive glass by weight, and the curing liquid comprises 0.5-5 parts of sodium carboxymethyl cellulose and 95-99.5 parts of normal saline by weight. The self-curing absorbable bone filling material provided by the present invention has a suitable setting time, good mechanical strength, injectability, anti-washing performance and good biological activity. It can promote cell ossification, is conducive to the formation of new bone in the middle and late stages, and avoids the infection problem existing after surgery.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biomaterials, and in particular to a self-curing absorbable bone filling material and application thereof. Background Art

[0002] Vertebral fractures or bone defects caused by osteoporosis are the most common diseases in the elderly population. It is difficult for the human body to heal such bone defects simply by relying on the self-repair function of the bone. Therefore, it is necessary to implant bone repair materials to heal and repair bone defects.

[0003] Bone cement is a common orthopedic repair material, which is widely used in bone defects, dentistry and plastic surgery. At present, most of the common bone cement materials on the market are polymethyl methacrylate bone cement (PMMA). PMMA is not absorbable in the human body, has low biological activity, and has no good bone induction ability. The material mixing system releases a large amount of heat during the curing process, causing damage to the tissue around the implant site. Therefore, it is necessary to find a more suitable orthopedic repair material. Traditional calcium phosphate bone cement consists of solid calcium phosphate powder and liquid phase, and the two can be cured in a physiological environment. Traditional calcium phosphate bone cement has good biological activity, bone induction and absorbability, and is more suitable for bone repair than polymethyl methacrylate bone cement, but it still has problems such as slow degradation time, low mechanical strength, poor injection performance, easy collapse, and inability to form a porous structure after in situ curing, which is not conducive to cell growth and the formation of new bone tissue.

[0004] A single surgical-grade calcium sulfate mixed with liquid has high initial strength and good injection properties, but has disadvantages such as short solidification time, poor anti-collapse, low mechanical strength, fast degradation time, and small pore size and porosity formed by in situ solidification, which is not conducive to the migration of osteoblasts and angiogenesis.

[0005] Bioactive glass (BAG) is a silicate glass composed of SiO2, Na2O, CaO and P2O5. Bioactive glass is the fastest bioactive material among currently synthesized bone repair materials. After implantation into the human body, a bioactive hydroxycarbonate apatite (HCA) layer is formed on the surface, providing a bonding interface for tissues, promoting the proliferation and growth of bone cells, activating the gene expression of bone cells, and accelerating the formation of new bones.

[0006] Sodium carboxymethyl cellulose is an important cellulose derivative obtained by chemical modification of natural cellulose. It is non-toxic, non-irritating, non-immunogenic and has good biocompatibility. It has unique properties such as viscosity, thickening, film-forming ability and water stability.

[0007] For example, US9433704B2 discloses a curable bone graft paste composition and a preparation method thereof, wherein the material comprises 20-60 parts of calcium sulfate (binder), 40-80 parts of bioactive glass and physiological saline (about 0.9% NaCl) or other similar fluids, with a solid-liquid ratio of 0.3-0.4 mL / g. However, the method does not contain a water-soluble thickener, the material has poor anti-washing ability before being injected into the bone defect and not solidified, and does not use porous bioactive glass and antibacterial components.

[0008] For example, US11338061B2 discloses a dynamic bioactive bone graft material with engineered porosity, which includes bioactive glass fibers and particles, additives, carriers and liquids. The additives include tricalcium phosphate, calcium phosphate, calcium sulfate, carboxymethyl cellulose, collagen, hydroxyapatite, antibacterial agents, antiviral drugs, vitamins, X-ray sunscreens, drugs, calcium, trace elements, metal oxides, nutrients or acids; silver, copper, strontium, magnesium or zinc; organic acids. The carrier includes collagen. The liquid includes blood, saline, glycerol, gelatin, plasma or bone marrow. The concept of porous bioactive glass drug loading is not used in this method.

[0009] For example, US2007026030A1 discloses a method for preparing rheological materials for bone and cartilage repair, wherein the materials include solid phase: methyl methacrylate, calcium sulfate, calcium phosphate, solid phase adhesive, bioactive glass, collagen, fibrin or hyaluronic acid, demineralized matrix, protein or polypeptide. The liquid phase is selected from one or more groups of water, aqueous solution, bone marrow aspirate, blood, resin, organic hardener, organic monomer and liquid biomolecule (the liquid component has sufficient fluidity or viscosity to pass through a needle with a specification of 22 or less and a length of at least 1.25 cm). Porous bioactive glass and antibacterial components are not used in this method.

[0010] For example, US6767550B1 discloses a hydroxyapatite-based drug delivery implant for treating cancer, wherein the material comprises a hydroxyapatite-based bioabsorbable material, doxorubicin (antibacterial component) and a liquid phase. The hydroxyapatite-based bioabsorbable material is selected from one or more materials of calcium phosphate, calcium sulfate, carbonated apatite, fluoroapatite, bioactive glass, biodegradable polymer, collagen and gelatin. The liquid phase is selected from distilled water and a buffer solution. However, in this method, the material does not contain a water-soluble thickener, and the material has poor anti-flushing and disintegration capabilities before being injected into the bone defect site and not solidified, and porous bioactive glass is not used.

[0011] For example, US2009318982A1 discloses a method for preparing an injectable calcium-based neutral, bioabsorbable bone graft, wherein the material includes a biodegradable calcium-based compound (calcium sulfate, hydroxyapatite and tricalcium phosphate), a biocompatible material, a bioincompatible material, a bonding powder and a binder (water, saline, serum or other neutral aqueous solution). However, the method does not contain a thickener anti-flushing component, the material has poor anti-flushing ability before being injected into a bone defect and not solidified, and porous bioactive glass is not used.

[0012] For example, US2023 / 0053789A1 discloses a bone transplant composition, wherein the material includes particles of hydroxyapatite, β-tricalcium phosphate, α-tricalcium phosphate and / or bioactive glass and a bioabsorbable polymer carrier. The carrier is selected from a bioabsorbable polymer, polyethylene glycol (PEG, 500 g / mol to about 3000 g / mol) or methylcellulose. However, the material provided by this method cannot be cured after being injected into the bone defect, does not have certain mechanical properties, and does not use porous bioglass and antibacterial components.

[0013] For example, CN102085389A discloses a method for preparing an injectable bone repair material, which includes 50%-90% α-calcium sulfate hemihydrate, 5%-45% bone powder particles (allogeneic bone), a biodegradable polymer and a nucleating agent, and a curing liquid, which may further include a plasticizer. Biodegradable polymers include but are not limited to hyaluronic acid, chitosan, alginate, carboxymethyl cellulose, octadecanoic acid, polysaccharides, etc. The nucleating agent is selected from at least one of calcium sulfate dihydrate, potassium sulfate and sodium sulfate. The plasticizer is selected from at least one of hyaluronic acid and its salts, calcium sulfate dihydrate, cellulose and its derivatives, octadecanoic acid, and glycerol, preferably carboxymethyl cellulose. The curing liquid is selected from at least one of physiological saline, water for injection or glucose injection. However, although the material provided by this method introduces allogeneic bone particles with a porous structure and good biocompatibility, it has the risk of spreading diseases and causing immune rejection with the host, and no antibacterial components are mentioned. The curing time of this injectable bone material is between 7 minutes and 125 minutes, and it has disadvantages such as difficult injection operation and long curing time.

[0014] CN111012792B discloses a biopolysaccharide flushing solution suitable for orthopedic surgery and a preparation method thereof, wherein the materials include 0.5% to 6% sodium carboxymethyl cellulose, 0.3% to 4% carboxymethyl chitosan, 5% to 20% bioglass, 0.01% to 0.1% acid-base regulator, and ultrapure water (balance). However, the material provided by the method is a flushing solution, which is suitable for orthopedic surgery but has a different mode of action (not injected into the bone defect).

[0015] CN110302431A discloses an injectable bioactive glass containing decalcified bone matrix DBM and its preparation method and application, wherein the material is composed of bioactive glass powder, DBM and 5-20wt% sodium carboxymethyl cellulose solution. However, the material provided by this method cannot be solidified after being injected into the bone defect, does not have certain mechanical properties, and does not use porous materials and antibacterial components.

[0016] CN106075565A discloses a self-curing and degradable bioactive paste bone repair material and its application, wherein the material comprises 15% to 30% of 45S5 bioactive glass, 30% to 45% of calcium sulfate hemihydrate, 30% to 40% of tricalcium silicate and a curing liquid. The curing liquid is selected from one or more of physiological saline, deionized water, carbonate solution, calcium chloride solution and phosphate solution. However, the material provided by the method does not contain a water-soluble thickener, and the material has poor anti-flushing ability before being injected into the bone defect site and not cured, and porous bioglass and antibacterial components are not used.

[0017] CN103800945B discloses a plastic bone repair material for bone repair and a preparation method thereof, wherein the material comprises 20 to 90 parts of α-calcium sulfate hemihydrate + hydroxyapatite, 20 to 40 parts of bioactive mineral powder, 10 to 80 parts of autologous bone powder particles or DBM particles, and a hydrogel in a total amount of 1:0.5 to 1:15 with the above raw materials. The hydrogel is preferably a PEO-PPO-PEO block copolymer solution. However, the material provided by the method does not use porous bioglass and antibacterial components.

[0018] CN114209878B discloses a solid phase powder for bone cement composite material and a bone cement composite material and application thereof, wherein the material comprises calcium phosphate powder (β-tricalcium phosphate, tetracalcium phosphate and monocalcium phosphate monohydrate), calcium sulfate hemihydrate powder, bioglass, hydroxyapatite and 5%-20% dipotassium hydrogen phosphate, 5%-20% potassium dihydrogen phosphate, 5%-10% citric acid, 1%-5% polymer compound and the balance water. However, the material provided by the method does not contain a water-soluble thickener, and does not use porous bioglass and antibacterial components.

[0019] CN110498664B discloses a method for preparing a high-strength injectable multiphase calcium phosphate-based bone cement, wherein the material comprises α-tricalcium phosphate powder, hemihydrate calcium sulfate powder, bioactive glass, polyglutamic acid and an aqueous solution of 3-10%wt meglumine. However, the material provided by the method does not contain a water-soluble thickener, and does not use porous bioglass and antibacterial components.

[0020] The existing methods cannot meet the actual clinical use requirements of bone filling materials and have certain shortcomings. Therefore, the development of a new injectable, flushing-resistant, self-curing absorbable bone filling material is of great significance for the medical use of bone defect filling. Summary of the invention

[0021] The technical problem to be solved by the present invention is that the existing self-curing absorbable bone filling materials have a long degradation time, small pore size and porosity of the in-situ curing materials, poor injection performance, easy disintegration during implantation, which is not conducive to osteoblast growth and blood vessel growth, easy to release a large amount of heat, and there is a problem of infection after surgery.

[0022] In order to solve the above technical problems, in a first aspect, the present invention provides a self-curing absorbable bone filling material, which comprises a solid-phase base component and a curing liquid, wherein the solid-phase base component comprises 40 to 60 parts of calcium sulfate hemihydrate and 40 to 60 parts of bioactive glass by weight, and the curing liquid comprises 0.5 to 5 parts of sodium carboxymethyl cellulose and 95 to 99.5 parts of normal saline by weight; the bioactive glass is a combination of 45S5BG and porous bioactive glass; the 45S5BG is composed of 45S5BG with a particle size of 0.5 to 200 μm and 45S5BG with a particle size of 500 to 1500 μm, and the porous bioactive glass is a combination of porous bioactive glass with a particle size of 0.5 to 200 μm and porous bioactive glass with a particle size of 500 to 1500 μm; the self-curing absorbable bone filling material also comprises 0.1 to 10 parts of antibacterial components.

[0023] The self-curing absorbable bone filling material provided by the present invention has a suitable setting time, good mechanical strength, injectability, anti-washing performance and good biological activity. It can promote cell ossification, is conducive to the formation of new bone in the middle and late stages, and avoids the infection problem after surgery.

[0024] The addition of bioactive glass to the solid phase substrate component of the present invention can stimulate and induce the expression of osteogenic genes, promote cell ossification, and facilitate the formation of new bone.

[0025] The calcium sulfate hemihydrate is 40-60 parts, for example, 40 parts, 45 parts, 50 parts, 55 parts or 60 parts.

[0026] The bioactive glass may be present in an amount of 40 to 60 parts, for example, 40 parts, 45 parts, 50 parts, 55 parts or 60 parts.

[0027] Preferably, the solid phase base component of the self-curing absorbable bone filling material includes 45-50 parts of calcium sulfate hemihydrate and 50-55 parts of bioactive glass by weight; the curing liquid includes 0.5-2 parts of sodium carboxymethyl cellulose and 98-99.5 parts of normal saline by weight; the bioactive glass is a combination of 45S5BG and porous bioactive glass; the 45S5BG is composed of 45S5BG with a particle size of 0.5-200 μm and 45S5BG with a particle size of 500-1500 μm, and the porous bioactive glass is composed of porous bioactive glass with a particle size of 0.5-200 μm and porous bioactive glass with a particle size of 500-1500 μm; the self-curing absorbable bone filling material also includes 5-10 parts of antibacterial components.

[0028] Preferably, the mass ratio of the porous bioactive glass to 45S5BG is 1:1-100.

[0029] Preferably, the 45S5BG can improve bioactivity and bone conductivity, wherein the porous bioactive glass can be used for drug loading and has a good sustained-release effect.

[0030] In the present invention, 45S5BG is prepared by the following method: in the laboratory, calcium source, silicon source, phosphorus source and sodium source powders are mixed uniformly, placed in a platinum crucible, and a high-temperature muffle furnace is set to a program: 0.5°C / min to 300°C, then 3°C / min to 1400°C and kept warm for 2 hours, from which the glass melts to a yellow-red liquid, the melted glass is poured into cold water, and quenched to obtain 45S5BG coarse particles. The coarse particles are placed in a ball mill jar and a ball mill is added to grind to obtain 45S5BG particles.

[0031] The porous bioactive glass in the present invention is a porous bioactive glass derived by a sol-gel method.

[0032] In the present invention, the porous bioactive glass is prepared by the following method: at room temperature, 4.0g of polyether P123 (Mn=5800) is dissolved in 60g of ethanol, 1.0g of 0.5M HCl solution is added, 6.7g of tetraethyl orthosilicate (TEOS), 0.73g of triethyl phosphate (TEP) and 1.4g of calcium nitrate tetrahydrate are added, mixed and stirred for 24h, poured into a glass dish and allowed to stand, and the solvent ethanol is volatilized, and the hydrolyzed SiO2 in the solvent is condensed and polymerized to form a gel block. The gel block is placed in an oven at 60°C and dried for 48h. The dried gel block is crushed and placed in a crucible, and the crucible is placed in a muffle furnace and heated to 650°C at a rate of ℃ / min and kept warm for 2h to obtain porous bioactive glass (MBG).

[0033] The particle size described in the present invention specifically refers to the equivalent particle size. When a certain physical property or physical behavior of the measured particle is closest to a homogeneous sphere (or combination) of a certain diameter, the diameter (or combination) of the sphere is taken as the equivalent particle size (or particle size distribution) of the measured particle.

[0034] In the present invention, bioactive glass is provided in different particle size ranges so that the degradation rate of the bone filling material matches the growth rate of new bone in the human body. Among them, the bioactive glass with a small particle size degrades faster in the early stage and has good biological activity; the degradation rate of the bioactive glass with a large particle size is not too fast, and mixing with calcium sulfate hemihydrate can improve the disadvantage of single calcium sulfate hemihydrate that degrades too quickly.

[0035] After the bone filling materials are implanted into the defect site, the small-particle 45S5BG and porous bioactive glass derived by the sol-gel method will be dissolved and degraded together with calcium sulfate hemihydrate in the early stage, resulting in an increase in the pH of the microenvironment, which can effectively inhibit bacteria and form a microporous structure on the surface of the bone filling material. The porous structure formed by the microporous structure and the undegraded large-particle bioactive glass has a certain porosity and pore size, which is conducive to the migration of osteoblasts and new blood vessels to the bioactive glass particle composition. In the later stage, the large-particle 45S5BG and the porous bioactive glass derived by the sol-gel method slowly degrade and resorb, stimulating and inducing the expression of osteogenic genes between the particle composition, promoting cell ossification, and facilitating the formation of new bone in the middle and late stages.

[0036] Preferably, the mass ratio of the 45S5BG with a particle size of 500-1500 μm to the 45S5BG with a particle size of 0.5-200 μm is 1:1-100, for example, it can be 1:1, 1:5, 1:10, 1:20, 1:40, 1:80, 1:100, etc.

[0037] Preferably, the mass ratio of the porous bioactive glass with a particle size of 500-1500 μm to the porous bioactive glass with a particle size of 0.5-200 μm is 1:1-100, for example, it can be 1:1, 1:5, 1:10, 1:20, 1:40, 1:80, 1:100, etc.

[0038] The present invention uses sodium carboxymethyl cellulose as a thickener, and the weight portion is 0.5 to 5 parts, for example, it can be 0.5 parts, 1 parts, 2 parts, 3 parts, 4 parts or 5 parts.

[0039] (1) Sodium carboxymethyl cellulose is non-toxic, non-irritating, non-immunogenic and has good biocompatibility.

[0040] (2) Sodium carboxymethyl cellulose curing liquid has certain viscosity and thickening properties, which can not only improve the injectability of bone filling materials during use, but also improve the anti-washing performance during the curing process (no migration and disintegration).

[0041] (3) Sodium carboxymethyl cellulose is a pore-forming agent. Since sodium carboxymethyl cellulose is a water-soluble thickener, after the bone filling material is injected into the defect site and solidified in situ, sodium carboxymethyl cellulose will slowly dissolve and absorb, which will form a porous structure on the surface of the bone filling material. Along with the dissolution of small-particle bioactive glass, the porosity of the bone filling material increases, and then a three-dimensional network structure is formed, which provides a place for cell metabolism, which is conducive to the formation of new bone tissue in the later stage. This solves the problems of small pore size and porosity of traditional in situ solidification materials, which are not conducive to osteoblast growth and blood vessel growth.

[0042] The physiological saline solution is 95 to 99.5 parts, for example, 95 parts, 96 parts, 97 parts, 98 parts, 99 parts or 99.5 parts.

[0043] The antibacterial component is 0.1 to 10 parts, for example, it can be 0.1 parts, 1 parts, 4 parts, 8 parts or 10 parts.

[0044] Preferably, the antibacterial component includes any one of gentamicin, vancomycin or rapamycin, or a combination of at least two of them.

[0045] In the present invention, the above antibiotics are selected to prevent infection and can reduce the incidence of infection to the greatest extent.

[0046] Preferably, the ratio of the solidifying liquid to the solid phase base component is 0.4 mL / g to 1 mL / g.

[0047] The solidifying liquid and the solid phase base component are mixed according to the ratio to obtain the slurry. The slurry in the range of 0.4mL / g ~1mL / g is neither too thin nor too thick, and has an appropriate solidification time. It has good extrudability and strong operability.

[0048] 1. When the ratio is greater than 1mL / g, the slurry is too thin. It is difficult to solidify when implanted into the human body. The solidification time is too long and the operation is difficult and difficult to control (all the slurry will be squeezed out with one force of the syringe).

[0049] 2. When the ratio is less than 0.4mL / g, the slurry is too thick, the syringe needs to exert great force, extrusion is difficult, and the solidification time is very short, leaving the doctor with a short time for surgical operation. During use, it is too thick to affect the performance, and the slurry cannot flow smoothly to fill the bone wound.

[0050] In the present invention, the preparation of the self-curing absorbable bone filling material is generally obtained by mixing raw materials, and there is no particular limitation. Preferably, the preparation method of the self-curing absorbable bone filling material has two forms: the first method is that the antibacterial component can be added in the form of a solid phase base component.

[0051] (1) First, prepare an antibacterial solution of a certain concentration; (2) fully immerse the porous bioactive glass derived by the sol-gel method in an antibacterial solution of a certain concentration, dry it, and then mix it with 45S5BG and calcium sulfate hemihydrate to obtain a solid phase base component; (3) use physiological saline as a solvent to prepare a thickener solution of a certain concentration to obtain a solidifying liquid; finally, combine the solidifying liquid and the solid phase base component to obtain a self-solidifying absorbable bone filling material.

[0052] The second method is to add the antimicrobial component in the form of a solidified liquid.

[0053] (1) 45S5BG, porous bioactive glass and calcium sulfate hemihydrate are mixed to obtain a solid phase substrate component.

[0054] (2) Fully dissolve the antibacterial ingredients in saline.

[0055] (3) Then, a certain amount of thickener is dissolved in the mixed solution of (2), and the mixture is stirred vigorously until the solution becomes clear to obtain a solidified liquid.

[0056] Finally, the solidifying liquid and the solid phase base component are combined to obtain a self-solidifying absorbable bone filling material.

[0057] In the above two methods, further, the solidifying liquid and the solid phase base component are mixed at a ratio of 0.4 mL / g to 1 mL / g to obtain an injectable, flushing-resistant self-solidifying absorbable bone filling material.

[0058] In a second aspect, the present invention provides a use of the self-curing absorbable bone filling material as described in the first aspect in the preparation of a bone injury repair medical device.

[0059] The self-curing absorbable bone filling material provided by the present invention has high application value in the actual medical field and can be prepared into different types of medical devices according to needs, which greatly improves the medical effect of filling bone defects.

[0060] For example, it can be used in orthopedic and dental surgeries in the future. Including bone defect repair: self-curing absorbable bone filling materials are used to fill the gaps in fractures, bone defects or bone transplants. They can quickly solidify and combine with surrounding bone tissue to promote bone regeneration. Spinal fusion surgery: self-curing absorbable bone filling materials are used to fill the intervertebral disc space and promote fusion between vertebrae, thereby stabilizing the spine. Dental surgery: self-curing absorbable bone filling materials are used for alveolar bone defect repair, bone augmentation before dental implant placement, and bone regeneration in periodontal disease treatment. Joint repair: In joint replacement surgery, self-curing absorbable bone filling materials can be used to fill bone defects around joints, provide mechanical support and promote bone healing. Osteoporotic fractures: self-curing absorbable bone filling materials are used to treat osteoporotic fractures, especially vertebral compression fractures, by filling and stabilizing bone structure, relieving pain and promoting healing.

[0061] The implementation of the present invention has the following beneficial effects:

[0062] The self-curing absorbable bone filling material provided by the present invention has a suitable setting time, good mechanical strength, injectability, anti-washing performance and good biological activity. It can promote cell ossification, is conducive to the formation of new bone in the middle and late stages, and avoids the infection problem after surgery. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figure 1 This is a picture of the extrusion of the bone filling material in Example 1.

[0064] Figure 2 This is a picture of the bone filling material in Example 1 after solidification and immersion in physiological saline for 24 hours.

[0065] Figure 3 This is the FTIR infrared spectrum of the bone filling material in Example 1 after being immersed in simulated body fluid for 24 hours.

[0066] Figure 4 Compressive strength diagram of the self-curing absorbable bone filling materials prepared in Examples 1-4.

[0067] Figure 5 1 is a degradation curve diagram of the self-curing absorbable bone filling material prepared in Example 1, Example 7 and Example 8.

[0068] Figure 6 This is a picture of the extrusion of the bone filling material in Comparative Example 1.

[0069] Figure 7 It is a degradation curve diagram of the bone filling material prepared in Example 1 (Y1) and Comparative Example 1 (D1).

[0070] Figure 83 is a degradation curve diagram of the self-curing absorbable bone filling material prepared in Example 1, Comparative Example 2 and Comparative Example 3. DETAILED DESCRIPTION

[0071] The specific embodiments of the present invention are described in detail below. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.

[0072] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0073] Example 1

[0074] This embodiment provides an injectable, flushing-resistant, self-curing absorbable bone filling material, and the specific preparation process is as follows:

[0075] (1) 1.6 g of sol-gel derived porous bioactive glass (1.0 g of 0.5-200 μm and 0.6 g of 500-1500 μm), 1.7 g of 45S5BG (1.0 g of 0.5-200 μm and 0.7 g of 500-1500 μm) and 2.3 g of calcium sulfate hemihydrate were mixed thoroughly to obtain a solid phase base component; (2) 1 g of sodium carboxymethyl cellulose was added to a beaker containing 99 g of normal saline, and the solution was stirred vigorously until it was clear to obtain a solidified liquid; (3) 5.6 g of the solid phase base component was weighed and mixed with 4.2 g of the solidified liquid, and the mixture was stirred to obtain an injectable, flushing-resistant self-solidifying absorbable bone filling material.

[0076] The setting time of the bone filling material in this embodiment was recorded as 21 min.

[0077] To evaluate the compressive strength of the bone filling material prepared in Example 1, the mixed filling material (slurry) in Example 1 was transferred to a cylindrical polytetrafluoroethylene mold, placed in an environment with a temperature of 37°C and a relative humidity of 100% for hydration for 3 days, and then taken out. Five parallel samples were taken. The bone filling material was a cylindrical shape of φ5*10mm, and the loading rate was 1.0mm / min. It was recorded as Y1. After 3 days, its compressive strength could reach 16.22±1.20MPa.

[0078] To evaluate the extrusion performance of the bone filling material prepared in Example 1, the mixed filling material in Example 1 was transferred into a syringe, and after standing for a few minutes, the bone filling material was extruded into a plastic culture dish. Figure 1As shown, the bone filling material can be extruded uniformly and has good extrusion performance.

[0079] To evaluate the anti-collapse performance of the bone filling material prepared in Example 1, after the bone filling material in the plastic culture dish solidified, physiological saline was added to immerse the bone filling material, and after 24 hours, the material was observed to be not collapsed. Figure 2 shown.

[0080] In order to evaluate the biological activity of the bone filling material prepared in Example 1, an in vitro immersion in simulated body fluid evaluation was performed. 1 g of the cured bone filling material was immersed in 200 mL of simulated body fluid for 24 h, and the wet sample was filtered out. The wet sample was repeatedly rinsed with ethanol and deionized water for several times, and then dried. The surface precipitate was scraped with a knife for infrared testing. Figure 3 This is the FTIR infrared reflectance spectrum of the bone filling material after being immersed in simulated body fluid for 24 hours. It can be seen that the reflection peak is 574cm -1 and 608cm -1 The appearance of indicates the formation of hydroxyapatite on the surface of the material, which means that the bone filling material has good biological activity.

[0081] The self-curing absorbable bone filling material was subjected to animal testing to verify its effectiveness.

[0082] The animal experiment used a model with a rabbit femoral condyle, a circular hole, and a bone defect with a diameter of 10 mm. In this bone defect model, the rabbit body cannot heal itself. In this bone defect model, bone filling materials were injected to verify the bone repair performance of bone filling materials. At 0 weeks, 8 weeks, and 12 weeks, micro-CT was used to observe the new bone growth at the bone defect site at different implantation periods, as shown in Table 1. Each sample has 3 parallel samples, recorded as (1), (2), and (3).

[0083] Table 1

[0084]

[0085] As shown in Table 1, as the implantation time of the bone filling material increases, the diameter of the bone defect gradually decreases, and the average bone defect diameter is 2.9 mm at 12 weeks. The bone filling material gradually degrades and is absorbed, and at the same time, new bone tissue around the defect grows from the outside to the inside. This shows that the self-curing absorbable bone filling material of the present invention can promote new bone formation in a 10 mm bone defect at the femoral condyle of rabbits.

[0086] Example 2

[0087] This embodiment provides an injectable, flushing-resistant, self-curing absorbable bone filling material, and the specific preparation process is as follows:

[0088] (1) 1.6 g of sol-gel derived porous bioactive glass (1.0 g of 0.5-200 μm and 0.6 g of 500-1500 μm), 1.7 g of 45S5BG (1.0 g of 0.5-200 μm and 0.7 g of 500-1500 μm) and 2.3 g of calcium sulfate hemihydrate were mixed thoroughly to obtain a solid phase base component; (2) 2 g of sodium carboxymethyl cellulose was added to a beaker containing 98 g of normal saline, and the solution was stirred vigorously until it was clear to obtain a solidified liquid; (3) 5.6 g of the solid phase base component was weighed and mixed with 4.2 g of the solidified liquid, and the mixture was stirred to obtain an injectable, anti-flushing, self-solidifying absorbable bone filling material.

[0089] The setting time of the bone filling material is 19 minutes.

[0090] To evaluate the compressive strength of the bone filling material prepared in Example 2, the mixed filling material (slurry) was transferred to a cylindrical polytetrafluoroethylene mold and placed in an environment with a temperature of 37°C and a relative humidity of 100% for hydration for 3 days. Five parallel samples were taken. The bone filling material was in the shape of a φ5*10mm cylinder and the loading rate was 1.0mm / min.

[0091] The bone filling material cured in this embodiment is obtained, which is denoted as Y2. After 3 days, the compressive strength thereof can reach 27.98±1.89 MPa.

[0092] Example 3

[0093] This embodiment provides an injectable, flushing-resistant, self-curing absorbable bone filling material, and the specific preparation process is as follows:

[0094] (1) 1.6 g of sol-gel derived porous bioactive glass (1.0 g of 0.5-200 μm and 0.6 g of 500-1500 μm), 1.7 g of 45S5BG (1.0 g of 0.5-200 μm and 0.7 g of 500-1500 μm) and 2.3 g of calcium sulfate hemihydrate were mixed thoroughly to obtain a solid phase base component; (2) 3 g of sodium carboxymethyl cellulose was added to a beaker containing 97 g of normal saline, and the solution was stirred vigorously until it was clear to obtain a solidified liquid; (3) 5.6 g of the solid phase base component was weighed and mixed with 4.2 g of the solidified liquid, and the mixture was stirred to obtain an injectable, flushing-resistant self-solidifying absorbable bone filling material.

[0095] The solidification time of the bone filling material in this embodiment is 16 minutes.

[0096] To evaluate the compressive strength of the bone filling material prepared in Example 3, the mixed filling material (slurry) was transferred to a cylindrical polytetrafluoroethylene mold, placed in an environment with a temperature of 37°C and a relative humidity of 100% for hydration for 3 days, and then taken out. Five parallel samples were taken. The bone filling material was a cylindrical shape of φ5*10mm, and the loading rate was 1.0mm / min. It was recorded as Y3. After 3 days, its compressive strength could reach 37.96±1.66MPa.

[0097] Example 4

[0098] This embodiment provides an injectable, flushing-resistant, self-curing absorbable bone filling material, and the specific preparation process is as follows:

[0099] (1) 1.6 g of sol-gel derived porous bioactive glass (1.0 g of 0.5-200 μm and 0.6 g of 500-1500 μm), 1.7 g of 45S5BG (1.0 g of 0.5-200 μm and 0.7 g of 500-1500 μm) and 2.3 g of calcium sulfate hemihydrate were mixed thoroughly to obtain a solid phase base component; (2) 4 g of sodium carboxymethyl cellulose was added to a beaker containing 96 g of normal saline, and the solution was stirred vigorously until it was clear to obtain a solidified liquid; (3) 5.6 g of the solid phase base component was weighed and mixed with 4.2 g of the solidified liquid, and the mixture was stirred to obtain an injectable, anti-flushing, self-solidifying absorbable bone filling material.

[0100] The solidification time of the bone filling material in this embodiment is 14 minutes.

[0101] To evaluate the compressive strength of the bone filling material prepared in Example 4, the mixed filling material (slurry) was transferred to a cylindrical polytetrafluoroethylene mold, placed in an environment with a temperature of 37°C and a relative humidity of 100% for hydration for 3 days, and then taken out. Five parallel samples were taken. The bone filling material was a cylindrical shape of φ5*10mm, and the loading rate was 1.0mm / min. It was recorded as Y4. After 3 days, its compressive strength could reach 46.57±3.74MPa.

[0102] Figure 4 is the compressive strength of the bone filling materials prepared in Examples 1-4 (respectively denoted as Y1, Y2, Y3 and Y4). Figure 4 It can be seen that as the content of sodium carboxymethylcellulose in the curing liquid increases, the compressive strength of the bone filling material will also increase.

[0103] Example 5

[0104] This embodiment provides an injectable, flushing-resistant, self-curing absorbable bone filling material, and the specific preparation process is as follows:

[0105] (1) 0.2 g of rapamycin was added to 10 mL of aqueous solution and stirred to obtain an antibacterial solution; (2) 1.6 g of porous bioactive glass derived by sol-gel method (0.8 g of 0.5-200 μm and 0.8 g of 500-1500 μm) was fully immersed in the antibacterial solution, dried, and then fully mixed with 1.7 g of 45S5BG (0.85 g of 0.5-200 μm and 0.85 g of 500-1500 μm) and 2.3 g of calcium sulfate hemihydrate to obtain a solid phase matrix component; (3) 1 g of sodium carboxymethyl cellulose was added to a beaker containing 99 g of normal saline, and stirred vigorously until it was clear to obtain a solidified liquid; (4) 5.5 g of the solid phase matrix component was weighed and mixed with 3.9 g of the solidified liquid to obtain an injectable, anti-flushing self-solidifying absorbable bone filling material.

[0106] Example 6

[0107] This embodiment provides an injectable, flushing-resistant, self-curing absorbable bone filling material, and the specific preparation process is as follows:

[0108] (1) 1.1 g of sol-gel derived porous bioactive glass (0.55 g of 0.5-200 μm and 0.55 g of 500-1500 μm), 1.3 g of 45S5BG (0.65 g of 0.5-200 μm and 0.65 g of 500-1500 μm) and 2.6 g of calcium sulfate hemihydrate were mixed thoroughly to obtain a solid phase base component; (2) 0.2 g of gentamicin was added to 10 mL of normal saline, and distilled water was added to 100 g and stirred to obtain an antibacterial solution; (3) 1.0 g of sodium carboxymethyl cellulose was added to the antibacterial solution, and the sodium carboxymethyl cellulose was vigorously stirred until the sodium carboxymethyl cellulose was dissolved to obtain a solid solution; (4) 6.0 g of the solid phase base component was weighed and mixed with 5.4 g of the solid solution to obtain an injectable, anti-flushing self-solidifying absorbable bone filling material.

[0109] Example 7

[0110] The difference between this embodiment and embodiment 1 is that the porous bioactive glass and 45S5BG derived by the sol-gel method in this embodiment only include small particles of bioactive glass. The specific preparation process is as follows:

[0111] (1) 1.6 g of sol-gel derived porous bioactive glass (0.5-200 μm), 1.7 g of 45S5BG (0.5-200 μm) and 2.3 g of calcium sulfate hemihydrate were mixed thoroughly to obtain a solid phase base component; (2) 1 g of sodium carboxymethyl cellulose was added to a beaker containing 99 g of normal saline, and the solution was stirred vigorously until it was clear to obtain a solidified liquid; (3) 5.6 g of the solid phase base component was weighed and mixed with 4.2 g of the solidified liquid, and the mixture was stirred to obtain an injectable, anti-flushing self-solidifying absorbable bone filling material.

[0112] The setting time of the bone filling material in this embodiment was recorded as 13 minutes.

[0113] In order to evaluate the degradation rate of the bone filling materials prepared in Example 1 and Example 7, the samples were immersed in Tris-HCl buffer solution in vitro. Tris-HCl / M 样品(固化后) = 200mL / g, and record the initial mass m0 of the material before immersion. Prepare 4 parallel samples during the test, and replace the Tris-HCl buffer solution at different times (0h, 12h, 24h, 72h, 120h, 168h (1W), 2W, 4W, 8W, 12W, 16W, 20W and 24W (6M)). Replace the buffer solution at each time point (every 24h if it exceeds 24h). Filter the sample and dry it at the observation point, and record the remaining mass m t , and then replace with new Tris-HCl buffer solution to obtain data.

[0114] According to the remaining mass% = (m t / m0)*100% to calculate the residual mass, thereby obtaining the degradation curves of the injectable, flushing-resistant, self-curing absorbable bone filling materials prepared in Example 1 and Example 7.

[0115] Example 8

[0116] The difference between this embodiment and embodiment 1 is that the porous bioactive glass and 45S5BG derived by the sol-gel method in this embodiment only include large particles of bioactive glass. The specific preparation process is as follows:

[0117] (1) 1.6 g of sol-gel derived porous bioactive glass (500-1500 μm), 1.7 g of 45S5BG (500-1500 μm) and 2.3 g of calcium sulfate hemihydrate were mixed thoroughly to obtain a solid phase base component; (2) 1 g of sodium carboxymethyl cellulose was added to a beaker containing 99 g of normal saline and stirred vigorously until the solution was clarified to obtain a solidified liquid; (3) 5.6 g of the solid phase base component was weighed and mixed with 4.2 g of the solidified liquid, and stirred to obtain an injectable, flushing-resistant self-solidifying absorbable bone filling material.

[0118] The setting time of the bone filling material in this embodiment was recorded as 26 minutes.

[0119] In order to evaluate the degradation rate of the bone filling materials prepared in Example 1 and Example 8, the samples were immersed in Tris-HCl buffer solution in vitro. Tris-HCl / M 样品(固化后)=200mL / g, and record the initial mass m0 of the material before immersion. Prepare 4 parallel samples during the test. Replace the Tris-HCl buffer solution at different times (0h, 12h, 24h, 72h, 120h, 168h (1W), 2W, 4W, 8W, 12W, 16W, 20W and 24W (6M / month)). Replace the buffer solution at each time point (every 24h if it exceeds 24h). Filter the sample and dry it at the observation point, and record the remaining mass m t , and then replace with new Tris-HCl buffer solution to obtain data.

[0120] According to the remaining mass% = (m t / m0)*100% to calculate the residual mass, thereby obtaining the degradation curves of the injectable, flushing-resistant, self-curing absorbable bone filling materials prepared in Example 1 and Example 8.

[0121] like Figure 5 The degradation curves of the injectable, flushing-resistant self-curing absorbable bone filling materials prepared in Example 1 (Y1), Example 7 (Y7) and Example 8 (Y8) are shown in FIG. Figure 5 .Depend on Figure 5 It can be seen that after immersion for 3 months (12W), the residual mass of Y1 is 4.3649±5.3659%, the residual mass of Y7 is 0, and the residual mass of Y8 is 70.2369±1.8954%. After immersion for 4 months (16W), the residual mass of Y1 is 0, and the residual mass of Y8 is 59.3698±1.4237%.

[0122] Clinically, the degradation rate of the expected sample matches the healing rate of new bone replacement in the human body. The degradation rate of Y7 is too fast, and it is completely degraded before the later stage of new bone tissue growth, which does not provide good bioactivity and bone guidance. The degradation rate is too slow (Y8) will hinder the formation of new bone tissue. According to the existing marketed product of the same variety (Novaboneputty) in clinical combined open reduction and internal fixation treatment of tibial fractures, the clinical and bone healing time of the experimental group is 11 to 12 weeks. This is consistent with the simulated degradation rate of Y1 (bioactive glass using a combination of large and small particles) in vitro, which can match the clinical bone healing time.

[0123] Comparative Example 1

[0124] The difference between this comparative example and Example 1 is that sodium carboxymethyl cellulose is not included in this comparative example, and the specific preparation process is as follows:

[0125] (1) 1.6 g of sol-gel derived porous bioactive glass (1.0 g of 0.5-200 μm and 0.6 g of 500-1500 μm), 1.7 g of 45S5BG (1.0 g of 0.5-200 μm and 0.7 g of 500-1500 μm) and 2.3 g of calcium sulfate hemihydrate were fully mixed to obtain a solid phase base component; (2) The solidifying liquid was normal saline (0.9% sodium chloride solution); (3) 5.6 g of the solid phase base component was weighed and mixed with 4.0 g of the solidifying liquid, and stirred to obtain an injectable, anti-flushing self-solidifying absorbable bone filling material, recorded as D1.

[0126] The solidification time of the bone filling material in this embodiment is 18 minutes.

[0127] To evaluate the extrusion performance of the bone filling material prepared in Comparative Example 1, the mixed filling material in Comparative Example 1 was transferred into a syringe, and after standing for a few minutes, the bone filling material was extruded into a plastic culture dish. Figure 6 This is a picture of the extrusion of the bone filling material in Comparative Example 1. Figure 1 It can be seen that the bone filling material of Example 1 can be extruded uniformly and has good extrusion performance, while the bone filling material of Comparative Example 1 is difficult to extrude, has uneven extrusion, is easy to break, etc. It can be seen that adding a certain amount of sodium carboxymethyl cellulose to the solidifying liquid can improve the injection performance, enable the material to be extruded uniformly and smoothly, and improve the use performance.

[0128] In order to evaluate the degradation rate of the bone filling materials prepared in Example 1 and Comparative Example 1, the samples were immersed in Tris-HCl buffer solution in vitro. Tris-HCl / M 样品(固化后) =200mL / g, and record the initial mass m0 of the material before immersion. Prepare 4 parallel samples during the test, and replace the Tris-HCl buffer solution at different times (0h, 12h, 24h, 72h, 120h, 168h (1W), 2W, 4W, 8W, 12W, 16W, 20W and 24W (6M / month)). Replace the buffer solution at each time point (every 24h if it exceeds 24h). Filter the sample and dry it at the observation point, record the remaining mass mt, and then replace the new Tris-HCl buffer solution to obtain the data. According to the residual mass %= (m t The residual mass is calculated by taking into account the degradation curves of the injectable, flushing-resistant, self-curing absorbable bone filling materials prepared in Example 1 (Y1) and Comparative Example 1 (D1).

[0129] like Figure 7As shown in the figure, during the first 72 h of immersion in Tris-HCl solution, the degradation rate of D1 was slightly faster than that of Y1. This is because Y1 contains sodium carboxymethyl cellulose, which acts as a plasticizer / stabilizer in the early stage of immersion. 2+ and Si 4+ The dissolution rate of Y1 was not as good as that of D1 solution. During the period from 72h to 24W, the degradation rate of Y1 was slightly faster. This was because sodium carboxymethyl cellulose was basically dissolved in the early stage of immersion, forming a multi- / microporous structure around Y1. This structure can increase the specific surface area of ​​Y1. At the microscopic level, the inorganic component Ca dissolved from Y1 2+ and Si 4+ The amount of Y1 is much greater than that of D1; macroscopically, this shows that the degradation rate of Y1 is faster than that of D1.

[0130] In conclusion, the dissolution of sodium carboxymethyl cellulose forms a multi- / microporous structure around Y1, which is beneficial to the formation of new bone in the later stage. This special structure is conducive to the crawling of cells, the growth of new blood vessels and new bone tissue.

[0131] Comparative Example 2

[0132] (1) 1.6 g of sol-gel derived porous bioactive glass (1.0 g of 0.5-200 μm and 0.6 g of 500-1500 μm), 1.7 g of 45S5BG (1.0 g of 300-425 μm and 0.7 g of 1700-2360 μm) and 2.3 g of calcium sulfate hemihydrate were mixed thoroughly to obtain a solid phase matrix component; (2) 1 g of sodium carboxymethyl cellulose was added to a beaker containing 99 g of normal saline, and the solution was stirred vigorously until it was clear to obtain a solidified liquid; (3) 5.6 g of the solid phase matrix component was weighed and mixed with 4.2 g of the solidified liquid, and the mixture was stirred to obtain an injectable, flushing-resistant, self-solidifying absorbable bone filling material.

[0133] Comparative Example 3

[0134] (1) 1.6 g of sol-gel derived porous bioactive glass (1.0 g of 300-425 μm and 0.6 g of 1700-2360 μm), 1.7 g of 45S5BG (1.0 g of 0.5-200 μm and 0.7 g of 500-1500 μm) and 2.3 g of calcium sulfate hemihydrate were mixed thoroughly to obtain a solid phase matrix component; (2) 1 g of sodium carboxymethyl cellulose solution was added to a beaker containing 99 g of normal saline, and stirred vigorously until it was clear to obtain a solidified liquid; (3) 5.6 g of the solid phase matrix component was weighed and mixed with 4.2 g of the solidified liquid, and stirred evenly to obtain an injectable, anti-washing self-solidifying absorbable bone filling material.

[0135] To evaluate the degradation rate of the bone filling materials prepared in Comparative Examples 2 and 3, the degradation rate of the bone filling materials prepared in Example 1 was evaluated by soaking in Tris-HCl buffer solution in vitro. Thus, the degradation curves of the injectable, anti-washing self-curing absorbable bone filling materials prepared in Comparative Examples 2 (D2) and 3 (D3) were obtained.

[0136] Depend on Figure 8 It can be seen that the residual mass of D2 and D3 at 12 W is 55.8388±3.5698% and 51.1235±5.3684%, respectively, which does not match the bone healing time rate in the clinic (around 12 W). In contrast, the residual mass of Y1 at 12 W is 5.3649±5.3659% (very small amount), which matches the bone healing rate in the clinic.

[0137] It can be seen that the bone filling material provided by the present invention matches the degradation rate of the bone filling material with the growth rate of new bone in the human body by matching the large and small particle size 45S5BG and porous bioactive glass. However, if the two bioactive glasses and the large and small particle size combinations are used, and the particle size range of the small particle size active glass is not 0.5-200 μm or the large particle size active glass is not 500-1500 μm, the in vitro degradation rate does not match the bone healing rate in the clinic, thus affecting the healing of bone tissue and resulting in poor results.

[0138] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A self-curing absorbable bone filling material, characterized in that: The self-curing absorbable bone filling material comprises a solid-phase base component and a curing liquid, wherein the solid-phase base component comprises 45-50 parts of calcium sulfate hemihydrate and 50-55 parts of bioactive glass by weight; the curing liquid comprises 0.5-2 parts of sodium carboxymethyl cellulose and 98-99.5 parts of normal saline by weight; the bioactive glass is a combination of 45S5BG and porous bioactive glass; the 45S5BG is composed of 45S5BG with a particle size of 0.5-200 μm and 45S5BG with a particle size of 500-1500 μm, and the porous bioactive glass is composed of porous bioactive glass with a particle size of 0.5-200 μm and porous bioactive glass with a particle size of 500-1500 μm; the self-curing absorbable bone filling material also comprises 5-10 parts of antibacterial components; The mass ratio of the porous bioactive glass to 45S5BG is 1:1-100; The mass ratio of the 45S5BG with a particle size of 500-1500 μm to the 45S5BG with a particle size of 0.5-200 μm is 1:1-100; the mass ratio of the porous bioactive glass with a particle size of 500-1500 μm to the porous bioactive glass with a particle size of 0.5-200 μm is 1:1-100; 45S5BG is prepared by the following method: in the laboratory, calcium source, silicon source, phosphorus source and sodium source powders are mixed evenly and placed in a platinum crucible. The high-temperature muffle furnace is set to a program: 0.5°C / min to 300°C, then 3°C / min to 1400°C and kept warm for 2 hours. From this time, the glass melts and becomes a yellow-red liquid. The melted glass is poured into cold water and quenched to obtain 45S5BG coarse particles. The coarse particles are placed in a ball mill and ground with a ball mill to obtain 45S5BG. The porous bioactive glass was prepared by the following method: 4.0 g of polyether P123, Mn=5800, was dissolved in 60 g of ethanol at room temperature, 1.0 g of 0.5 M HCl solution, 6.7 g of tetraethyl orthosilicate, 0.73 g of triethyl phosphate and 1.4 g of calcium nitrate tetrahydrate were added, the mixture was mixed and stirred for 24 hours, and then poured into a glass dish and allowed to stand until the solvent ethanol evaporated, and the hydrolyzed SiO2 in the solvent was condensed and polymerized to form a gel block, the gel block was placed in an oven at 60°C and dried for 48 hours, the dried gel block was crushed and placed in a crucible, the crucible was placed in a muffle furnace and heated to 650°C and kept warm for 2 hours to obtain the porous bioactive glass.

2. The self-curing absorbable bone filling material according to claim 1, characterized in that: The antibacterial component includes any one of gentamicin, vancomycin or rapamycin, or a combination of at least two of them.

3. The self-curing absorbable bone filling material according to claim 1, characterized in that: The ratio of the solidifying liquid to the solid phase base component is 0.4 mL / g to 1 mL / g.

4. Use of the self-curing absorbable bone filling material according to any one of claims 1 to 3 in the preparation of medical equipment for repairing bone damage.